249 related articles for article (PubMed ID: 31281052)
1. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
He Z; Wu X; Ma S; Zhang C; Zhang Z; Wang S; Yu S; Wang Q
Clin Lung Cancer; 2019 Sep; 20(5):e548-e551. PubMed ID: 31281052
[No Abstract] [Full Text] [Related]
2. Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.
Luo J; Gu D; Lu H; Liu S; Kong J
J Thorac Oncol; 2019 Dec; 14(12):e266-e268. PubMed ID: 31757376
[No Abstract] [Full Text] [Related]
3. A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.
Li M; Tang Q; Chen S; Wang Y
Lung Cancer; 2021 Jan; 151():98-100. PubMed ID: 33280926
[No Abstract] [Full Text] [Related]
4. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing.
Zhu YC; Wang WX; Xu CW; Zhang QX; Du KQ; Chen G; Lv TF; Song Y
Ann Oncol; 2018 Dec; 29(12):2392-2393. PubMed ID: 30339198
[No Abstract] [Full Text] [Related]
6. A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma.
Fei X; Zhu L; Zhou H; Qi C; Wang C
J Thorac Oncol; 2019 Sep; 14(9):e191-e193. PubMed ID: 31445731
[No Abstract] [Full Text] [Related]
7. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.
Vendrell JA; Taviaux S; Béganton B; Godreuil S; Audran P; Grand D; Clermont E; Serre I; Szablewski V; Coopman P; Mazières J; Costes V; Pujol JL; Brousset P; Rouquette I; Solassol J
Sci Rep; 2017 Oct; 7(1):12510. PubMed ID: 28970558
[TBL] [Abstract][Full Text] [Related]
8. Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib.
Chen X; Zhao G; Zhong P; Zhang M; Chen R; Zhang D
Clin Lung Cancer; 2020 Nov; 21(6):e564-e566. PubMed ID: 32576444
[No Abstract] [Full Text] [Related]
9. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
[TBL] [Abstract][Full Text] [Related]
10. Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib.
Wang YL; Wu ZZ; Zhang HR; Chen DS; Zhao X
Lung Cancer; 2021 Apr; 154():216-218. PubMed ID: 33637344
[No Abstract] [Full Text] [Related]
11. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma.
Wang L; Li L; Zhou X; Zhang D
Lung Cancer; 2024 May; 191():107797. PubMed ID: 38669726
[No Abstract] [Full Text] [Related]
13. A novel SETD3-ALK fusion in lung adenocarcinoma and sustained clinical response to crizotinib.
Dai S; Liu XQ; Wu Q; Du CM; Liu Q; Xue YY; Luo F; Li Y
Lung Cancer; 2023 Jan; 175():121-124. PubMed ID: 36495785
[TBL] [Abstract][Full Text] [Related]
14. SRBD1-ALK, a Novel ALK Fusion Gene Identified in an Adenocarcinoma Patient by Next-Generation Sequencing.
Hou X; Xu H; Chen L
J Thorac Oncol; 2019 Apr; 14(4):e72-e73. PubMed ID: 30922581
[No Abstract] [Full Text] [Related]
15. Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib.
Zhao G; Chen L; Xiao M; Yang S
Lung Cancer; 2021 Feb; 152():189-192. PubMed ID: 33419583
[No Abstract] [Full Text] [Related]
16. SMPD3-ALK: A novel ALK fusion gene in lung adenocarcinoma.
Liang Y; Wang Y; Wang W; Zhao J; Xu M; Zheng M
Clin Genet; 2021 Mar; 99(3):488-489. PubMed ID: 33556194
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
[TBL] [Abstract][Full Text] [Related]
18. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
Wu X; Wang W; Zou B; Li Y; Yang X; Liu N; Ma Q; Zhang X; Wang Y; Li D
Thorac Cancer; 2020 Jun; 11(6):1695-1698. PubMed ID: 32212216
[TBL] [Abstract][Full Text] [Related]
19. A novel
Pan X; Zhong A; Xing Y; Li X; Du H; Shi M
J Int Med Res; 2021 Sep; 49(9):3000605211044652. PubMed ID: 34590916
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib.
Qin BD; Jiao XD; Liu K; Wu Y; Zang YS
J Thorac Oncol; 2019 Jun; 14(6):e115-e117. PubMed ID: 31122560
[No Abstract] [Full Text] [Related]
[Next] [New Search]